{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-059569","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.123911+00:00","generated_at":"2026-05-23T04:25:01.904360+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Repligen Q1 revenue $169M (+10% YoY); adjusted EPS $0.39 vs $0.30; orders up high-teens","bullets":["Revenue $169M, up 10% reported, 14% organic non-COVID YoY; GAAP EPS $0.10, adjusted EPS $0.39.","Adjusted operating income $23M, up 72% YoY; adjusted gross margin 53.7% vs 49.2%.","Orders grew high-teens YoY with all four franchises up double-digits; biopharma and consumables record ex-COVID.","FY2025 guidance reiterated: organic growth 9.5%-13.5%; adjusted EPS $1.63-$1.72.","Closed acquisition of 908 Devices' bioprocessing portfolio; minimal tariff impact expected."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-059569","json":"https://secwatch.observer/filing/0000950170-25-059569.json","markdown":"https://secwatch.observer/filing/0000950170-25-059569.md","text":"https://secwatch.observer/filing/0000950170-25-059569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000095017025059569/0000950170-25-059569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000095017025059569/rgen-20250429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T04:25:01.904360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}